Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic
Christian Müller, MD
Advertisement
Articles by Christian Müller, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5